ResearcherAmsterdam University Medical CentersActive in the last 2 years
Alessandro Gregori
Matched on ORCID iD 0000-0002-9951-2211; OpenAlex author ID A5076652088. Sources: OpenAlex.
Their work
- Papers
- 10 (first author 5, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 35
2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 4 papers
Papers 10
- Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant Pancreatic Cancer Cells. First author DOI 10.1016/j.ijrobp.2023.10.035↗
- Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems. First author DOI 10.1016/j.semcancer.2024.09.002↗
- ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells. First author DOI 10.1186/s13046-023-02879-8↗
- Altered Mechanobiology of PDAC Cells with Acquired Chemoresistance to Gemcitabine and Paclitaxel. Co-author DOI 10.3390/cancers16223863↗
- Prognostic Significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.3390/cancers15030628↗
- Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. Co-author DOI 10.1016/j.drup.2022.100864↗
- Biodegradable Ultrasmall-in-Nano Architectures Loaded with Cisplatin Prodrug in Combination with Ionizing Radiation Induces DNA Damage and Apoptosis in Pancrea… Co-author DOI 10.3390/cancers14123034↗
- Antibiotics and Adverse Events in Patients with Pancreatic Cancer Treated with Gemcitabine: Looking for Novel Clinical and Preclinical Insights. First author DOI 10.1002/onco.13606↗
- Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models. First author DOI 10.1186/s40164-020-00176-0↗
- "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Up… Co-author DOI 10.3390/cancers12113206↗
Closest collaborators
The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elisa Giovannetti · 10 shared papers, 2020–2024 · strength 1.64
- Paper Altered Mechanobiology of PDAC Cells with Acquired Chemoresistance to Gemcitabine and Paclitaxel. DOI 10.3390/cancers16223863↗
- Paper Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model sys… DOI 10.1016/j.semcancer.2024.09.002↗
- Paper Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant Pancreatic Cancer Cell… DOI 10.1016/j.ijrobp.2023.10.035↗
- Mjriam Capula · 5 shared papers, 2022–2024 · strength 0.88
- Paper Altered Mechanobiology of PDAC Cells with Acquired Chemoresistance to Gemcitabine and Paclitaxel. DOI 10.3390/cancers16223863↗
- Paper ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pan… DOI 10.1186/s13046-023-02879-8↗
- Paper Prognostic Significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in… DOI 10.3390/cancers15030628↗
- Thomas Schmidt · 4 shared papers, 2023–2024 · strength 0.76
- Paper Altered Mechanobiology of PDAC Cells with Acquired Chemoresistance to Gemcitabine and Paclitaxel. DOI 10.3390/cancers16223863↗
- Paper Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant Pancreatic Cancer Cell… DOI 10.1016/j.ijrobp.2023.10.035↗
- Paper ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pan… DOI 10.1186/s13046-023-02879-8↗
- Erik H.J. Danen · 4 shared papers, 2023–2024 · strength 0.76
- Paper Altered Mechanobiology of PDAC Cells with Acquired Chemoresistance to Gemcitabine and Paclitaxel. DOI 10.3390/cancers16223863↗
- Paper Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant Pancreatic Cancer Cell… DOI 10.1016/j.ijrobp.2023.10.035↗
- Paper ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pan… DOI 10.1186/s13046-023-02879-8↗
- Cecilia Bergonzini · 4 shared papers, 2023–2024 · strength 0.76
- Paper Altered Mechanobiology of PDAC Cells with Acquired Chemoresistance to Gemcitabine and Paclitaxel. DOI 10.3390/cancers16223863↗
- Paper Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant Pancreatic Cancer Cell… DOI 10.1016/j.ijrobp.2023.10.035↗
- Paper ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pan… DOI 10.1186/s13046-023-02879-8↗
- Pei Pei · 3 shared papers, 2020–2024 · strength 0.46
- Paper Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant Pancreatic Cancer Cell… DOI 10.1016/j.ijrobp.2023.10.035↗
- Paper Biodegradable Ultrasmall-in-Nano Architectures Loaded with Cisplatin Prodrug in Combination with Ionizing Radiation Ind… DOI 10.3390/cancers14123034↗
- Paper Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models. DOI 10.1186/s40164-020-00176-0↗
- Liam Andrew McDonnell · 2 shared papers, 2024 · strength 0.36
- Paper Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant Pancreatic Cancer Cell… DOI 10.1016/j.ijrobp.2023.10.035↗
- Paper ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pan… DOI 10.1186/s13046-023-02879-8↗
- Macarena Perán · 2 shared papers, 2022–2024 · strength 0.35
- Paper Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model sys… DOI 10.1016/j.semcancer.2024.09.002↗
- Paper Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic ca… DOI 10.1016/j.drup.2022.100864↗
- Dongmei Deng · 2 shared papers, 2021–2022 · strength 0.32
- Paper Antibiotics and Adverse Events in Patients with Pancreatic Cancer Treated with Gemcitabine: Looking for Novel Clinical … DOI 10.1002/onco.13606↗
- Paper Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic ca… DOI 10.1016/j.drup.2022.100864↗
- Adam Enver Frampton · 2 shared papers, 2020–2024 · strength 0.29
- Paper Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant Pancreatic Cancer Cell… DOI 10.1016/j.ijrobp.2023.10.035↗
- Paper "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influenci… DOI 10.3390/cancers12113206↗
- Ingrid Garajová · 2 shared papers, 2020–2024 · strength 0.28
- Paper ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pan… DOI 10.1186/s13046-023-02879-8↗
- Paper "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influenci… DOI 10.3390/cancers12113206↗
- Godefridus J. Peters · 2 shared papers, 2020 · strength 0.23
- Benoît Immordino · 1 shared paper, 2024 · strength 0.19
- Manoj Amrutkar · 1 shared paper, 2024 · strength 0.19
- Naomi Walsh · 1 shared paper, 2024 · strength 0.19
- Cristina P. R. Xavier · 1 shared paper, 2024 · strength 0.19
- Rita Rebelo · 1 shared paper, 2024 · strength 0.19
- Belén Toledo · 1 shared paper, 2024 · strength 0.19
- Giulia Lencioni · 1 shared paper, 2024 · strength 0.19
- Justo Pastor Castano · 1 shared paper, 2024 · strength 0.19
- Asia Botto · 1 shared paper, 2024 · strength 0.18
- Annalisa Comandatore · 1 shared paper, 2023 · strength 0.16
- Fatemeh Khojasteh‐Leylakoohi · 1 shared paper, 2023 · strength 0.16
- Luca Morelli · 1 shared paper, 2023 · strength 0.16
- Amir Avan · 1 shared paper, 2023 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.